Showing results (1071-1080 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|September 16, 2024
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)Alessandro Troiani, Maria Martinez, Caroline Ward, et al.
Future Oncology (London, England)|September 16, 2024
The prognostic implications of radiologic extranodal extension in the lymph nodes of patients with nasopharyngeal cancerPingting Zhou, Yunxiu Luo, Chenxi Wang, et al.
Future Oncology (London, England)|September 16, 2024
Are 19del and L858R really different disease entities?Seoree Kim, Yunseok Heo, Young-Ho Lee, et al.
Future Oncology (London, England)|September 13, 2024
The role of multiparametric MRI in predicting lymphovascular invasion in breast cancer patientsJinhua Wang, Siqing Jing, Zhongxian Yang, et al.
Future Oncology (London, England)|September 12, 2024
The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapyJuanjuan Shen, Nanbao Zhong, Zhonghua Chen, et al.
Future Oncology (London, England)|September 13, 2024
T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomasZhenhua Wang, Jinzhong Shu, Linjun Feng
Future Oncology (London, England)|September 12, 2024
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety studyIsabel María Carrión-Madroñal, Rocío Díaz-Acedo, Santiago José Lora-Escobar, et al.
Future Oncology (London, England)|October 14, 2024
Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysisJia Qin Cai, Yi Ming Wang, Xinmiao Lin, et al.
Future Oncology (London, England)|October 8, 2024
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancerCharles D Lopez, Adel Kardosh, Emerson Y Chen, et al.
Future Oncology (London, England)|October 10, 2024
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trialEhab L Atallah, Michael J Mauro, Koji Sasaki, et al.
Pageof 452